Inhibition of KIF20A by BKS0349 reduces endometriotic lesions in a xenograft mouse model
article
OA: closed
CC0
⤵ 1 in-corpus citation
AI-generated summary
Inhibition of KIF20A by BKS0349 reduced endometriotic lesion size in mice by decreasing proliferation and increasing apoptosis.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Several studies have suggested a possible etiological association between ovarian endometriosis and ovarian cancer. Evidence has shown that KIF20A overexpression might confer a malignant phenotype to ovarian tumors by promoting proliferation and inhibiting apoptosis. However, no data about the role of KIF20A in endometriosis have been described. In this study, the human endometrium (n = 4) was transfected by mCherry adenovirus and intraperitoneally implanted in mice. Subsequently, mice were divided in three groups (n = 8/group) that were treated with Vehicle, BKS0349 (KIF20A-antagonist) or cabergoline (dopamine receptor agonist) for 21 days. mCherry-labeled endometriotic lesions were monitored over time using the IVIS Imaging System. Mice were sacrificed 72 h after the last administration; proliferation was evaluated by immunohistochemistry and apoptosis by TUNEL. CCND1 gene expression (G1 phase-related gene) was measured by qRT-PCR. A significant reduction in mCherry-fluorescent signal was observed in the BKS0349 group after treatment ended (D24) compared with D0 (P-value = 0.0313). Moreover, the mCherry signal on D24 showed a significant decrease in the BKS0349 group compared with controls (P-value = 0.0303), along with significant size reduction of endometriotic lesions observed in the BKS0349 group compared with control on D24 (P-value = 0.0006). Functional studies showed a significant reduction in proliferating cells in the BKS0349-treated group compared with controls (P-value = 0.0082). In addition, CCND1 expression was decreased in the BKS0349 group compared with control (P-value = 0.049) at D24 and a significant increase in apoptotic cells among endometriotic lesions in BKS0349-treated mice was observed compared with control (P-value = 0.0317). Based on these findings, we concluded that BKS0349 induces apoptosis and inhibits cell proliferation, reducing endometriotic lesion size and suggesting KIF20A inhibition by BKS0349 as a novel therapeutic treatment for endometriosis.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (38)
- Association between endometriosis and cancer: A comprehensive review and a critical analysis of clinical and epidemiological evidence via openalex
- Dopamine agonist administration causes a reduction in endometrial implants through modulation of angiogenesis in experimentally induced endometriosis via openalex
- Endometriosis via openalex
- Endometriosis and infertility via openalex
- Endometriosis and Ovarian Cancer: A Systematic Review via openalex
- Endometriosis-associated Ovarian Cancers via openalex
- ESHRE guideline for the diagnosis and treatment of endometriosis via openalex
- Evaluation of the potential therapeutic effects of a double-stranded RNA mimic complexed with polycations in an experimental mouse model of endometriosis via openalex
- Immunohistochemistry expression of targeted therapies biomarkers in ovarian clear cell and endometrioid carcinomas (type I) and endometriosis via openalex
- Ovarian Clear Cell Carcinoma Detected During Long-Term Management of Endometriotic Cysts in Young Patients: Possible Heterogeneity of this Tumor via openalex
- The effects of ergot and non-ergot-derived dopamine agonists in an experimental mouse model of endometriosis via openalex
- Use of GnRH antagonists in the treatment of endometriosis via openalex
- W2149628033 via openalex
- W2214130360 via openalex
- W2267202447 via openalex
- W2333064082 via openalex
- W2568780291 via openalex
- W2570928071 via openalex
- W2766252994 via openalex
- W2800519601 via openalex
- W2829901800 via openalex
- W2887867975 via openalex
- W2889679977 via openalex
- W2891537241 via openalex
- W2904061041 via openalex
- W4211081176 via openalex
- W6750911915 via openalex
- W1982440526 via openalex
- W1985481481 via openalex
- W1996637041 via openalex
- W2014620140 via openalex
- W2030574228 via openalex
- W2057178621 via openalex
- W2060623598 via openalex
- W2079190330 via openalex
- W2100096634 via openalex
- W2119834455 via openalex
- W2133408651 via openalex
Cited by (1)
Source provenance
- europepmc
- last seen: 2026-08-06T06:07:45.168820+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:22:41.077124+00:00
- unpaywall
- last seen: 2026-08-06T06:41:17.185923+00:00
License: CC0
· commercial use OK